Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors

Nature Genetics

Volumn 48, Issue 6, 2016, Pages 600-606

  Kim, Jaegil ^a   Mouw, Kent W ^b,c   Polak, Paz ^a,c,d   Braunstein, Lior Z ^a,c   Kamburov, Atanas ^a,c,d   Tiao, Grace ^a   Kwiatkowski, David J ^b,c   Rosenberg, Jonathan E ^e   Van Allen, Eliezer M ^a,c,f   D'Andrea, Alan D ^b,c,f   Getz, Gad ^a,c,d  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ERCC2 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENETIC ASSOCIATION; HUMAN; MISSENSE MUTATION; PRIORITY JOURNAL; SMOKING; SOMATIC MUTATION; UROGENITAL TRACT TUMOR; COHORT ANALYSIS; GENETICS; MUTATION; TOBACCO; URINARY BLADDER NEOPLASMS; VALIDATION STUDY;

COHORT STUDIES; DNA DAMAGE; DNA REPAIR; HUMANS; MUTATION; TOBACCO; URINARY BLADDER NEOPLASMS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84964308124     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3557     Document Type: Article

References (48)

1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011
2. Dietlein, F., Thelen, L., & Reinhardt, H.C. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 30, 326-339 (2014
3. Garraway, L.A., & Lander, E.S. Lessons from the cancer genome. Cell 153, 17-37 (2013
4. Alexandrov, L.B., et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
5. Kasar, S., et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015
6. Helleday, T., Eshtad, S., & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15, 585-598 (2014
7. Marteijn, J.A., Lans, H., Vermeulen, W., & Hoeijmakers, J.H. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell Biol. 15, 465-481 (2014
8. Lawrence, M.S., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013
9. Fuss, J.O., & Tainer, J.A. XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. DNA Repair (Amst) 10, 697-713 (2011
10. Compe, E., & Egly, J.M. TFIIH: when transcription met DNA repair. Nat. Rev. Mol. Cell Biol. 13, 343-354 (2012
11. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014
12. Van Allen, E.M., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140-1153 (2014
13. Guo, G., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45, 1459-1463 (2013
14. Yap, K.L., et al. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin. Cancer Res. 20, 6605-6617 (2014
15. Freedman, N.D., Silverman, D.T., Hollenbeck, A.R., Schatzkin, A., & Abnet, C.C. Association between smoking and risk of bladder cancer among men and women. J. Am. Med. Assoc. 306, 737-745 (2011
16. Ploeg, M., Aben, K.K., & Kiemeney, L.A. The present and future burden of urinary bladder cancer in the world. World J. Urol. 27, 289-293 (2009
17. Benhamou, S., et al. DNA adducts in normal bladder tissue and bladder cancer risk. Mutagenesis 18, 445-448 (2003
18. Lee, H.W., et al. Acrolein-and 4-aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. Oncotarget 5, 3526-3540 (2014
19. Talaska, G., al-Juburi, A.Z., & Kadlubar, F.F. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc. Natl. Acad. Sci. USA 88, 5350-5354 (1991
20. Gao, W., et al. Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol. Rep. 24, 257-262 (2010
21. Stern, M.C., et al. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the International Consortium of Bladder Cancer. Cancer Res. 69, 6857-6864 (2009
22. Tan, V.Y., & Févotte, C. Automatic relevance determination in nonnegative matrix factorization with the β-divergence. IEEE Trans. Pattern Anal. Mach. Intell. 35, 1592-1605 (2013
23. Nik-Zainal, S., et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 46, 487-491 (2014
24. Roberts, S.A., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970-976 (2013
25. Poon, S.L., et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 5, 197ra101 (2013
26. Schmeiser, H.H., Schoepe, K.B., & Wiessler, M. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9, 297-303 (1988
27. Hoang, M.L., et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 5, 197ra102 (2013
28. Poon, S.L., et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med. 7, 38 (2015
29. Kamburov, A., et al. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc. Natl. Acad. Sci. USA 112, E5486-E5495 (2015
30. Kumar, P., Henikoff, S., & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073-1081 (2009
31. Pfeifer, G.P., et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21, 7435-7451 (2002
32. Francioli, L.C., et al. Genome-wide patterns and properties of De novo mutations in humans. Nat. Genet. 47, 822-826 (2015
33. Green, P., et al. Transcription-associated mutational asymmetry in mammalian evolution. Nat. Genet. 33, 514-517 (2003
34. Haradhvala, N.J., et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538-549 (2016
35. Polak, P., & Arndt, P.F. Transcription induces strand-specific mutations at the 5′ end of human genes. Genome Res. 18, 1216-1223 (2008
36. Alexandrov, L.B., et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402-1407 (2015
37. Groenendijk, F.H., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur. Urol. 69, 384-388 (2016
38. Plimack, E.R., et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959-967 (2015
39. Bellmunt, J., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 18, 522-528 (2007
40. Walsh, C.S., et al. ERCC5 is a novel biomarker of ovarian cancer prognosis. J. Clin. Oncol. 26, 2952-2958 (2008
41. Jansen, J.G., Tsaalbi-Shtylik, A., & De Wind, N. Roles of mutagenic translesion synthesis in mammalian genome stability, health and disease. DNA Repair (Amst) 29, 56-64 (2015
42. Sale, J.E., Lehmann, A.R., & Woodgate, R. Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat. Rev. Mol. Cell Biol. 13, 141-152 (2012
43. Nik-Zainal, S., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012
44. Strona, G., Nappo, D., Boccacci, F., Fattorini, S., & San-Miguel-Ayanz, J. A fast and unbiased procedure to randomize ecological binary matrices with fixed row and column totals. Nat. Commun. 5, 4114 (2014
45. Lee, D.D., & Seung, H.S. Learning the parts of objects by non-negative matrix factorization. Nature 401, 788-791 (1999
46. Subramanian, A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
47. Carter, S.L., et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012
48. Landau, D.A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013